Self-Funded Employer Plans (ASO)

How Self-Funded Employer Plans (ASO) approaches GLP-1 coverage

Self-funded (ASO — Administrative Services Only) plans are governed by ERISA, not state mandates. The employer — not the carrier whose logo is on your ID card — decides what's covered; the carrier merely administers claims. Two employees with identical "Aetna" cards can have completely different GLP-1 coverage. For T2D indications (Ozempic, Mounjaro, Rybelsus), most large self-funded plans include coverage subject to prior authorization with A1c documentation and step therapy through metformin; verify with your specific plan and current formulary. For weight-loss indications (Wegovy, Zepbound, Saxenda), coverage is far less predictable: many large employers exclude anti-obesity medications, and those that cover often add BMI thresholds, lifestyle-program prerequisites, or duration caps; verify with your specific plan and current formulary. Some employers cover Wegovy specifically for the cardiovascular risk reduction indication (post-SELECT) while excluding weight-loss use; verify with your specific plan and current formulary.

Statutory and structural notes

Self-funded plans are regulated under ERISA (29 U.S.C. §1001 et seq.) and exempt from state insurance mandates via ERISA preemption (29 U.S.C. §1144). ACA essential health benefits do not apply to large-group self-funded plans, and EHBs do not include weight-loss drugs regardless. Employers retain near-total discretion over formulary design, exclusions, and PA criteria, provided the plan document is applied consistently.

Typically considered for coverage

The list below reflects general patterns observed across Self-Funded Employer Plans (ASO)plan documents. Coverage for any specific drug, dose, or indication must be confirmed against your own plan's current formulary and medical policy.

• Ozempic for T2D — typically covered with PA requiring A1c documentation; verify with your specific plan and current formulary
• Mounjaro for T2D — typically covered with PA and often step therapy through metformin; verify with your specific plan and current formulary
• Rybelsus for T2D — coverage varies, often non-preferred tier; verify with your specific plan and current formulary
• Wegovy for cardiovascular risk reduction (post-SELECT indication) — may be covered by plans that include it for this indication; verify with your specific plan and current formulary
• Zepbound for obstructive sleep apnea (OSA indication added 2024) — may be covered by plans that include it for OSA; verify with your specific plan and current formulary
• Wegovy/Zepbound/Saxenda for weight management — coverage varies dramatically by employer; some cover with BMI ≥30 (or ≥27 with comorbidity) plus lifestyle-program enrollment, many exclude entirely; verify with your specific plan and current formulary

Typically excluded

• Anti-obesity medications under employers that have adopted a categorical AOM exclusion (common among cost-sensitive mid-market employers)
• Compounded semaglutide/tirzepatide — virtually universally excluded by PBMs as non-FDA-approved
• Off-label weight-loss use of T2D-labeled GLP-1s (Ozempic, Mounjaro, Rybelsus) — PBM PA systems block weight-loss diagnoses
• Coverage beyond a duration cap (e.g., 12- or 24-month lifetime maximum) imposed by some employers
• GLP-1 use without completion of required lifestyle/wellness program prerequisites where mandated
• Refills without documented weight-loss progress milestones (e.g., ≥5% loss at 6 months) where employer plan requires it

Prior authorization

Prior authorization is commonly required for GLP-1 medications under Self-Funded Employer Plans (ASO) plans. Your prescriber typically submits a PA form with diagnosis codes, lab results (e.g., A1c for T2D, BMI for weight management), documented prior therapy attempts, and clinical justification.

Appeal strategy if denied

Appeals follow ERISA's claims procedure (29 CFR §2560.503-1): request the Summary Plan Description and plan document, then file a written internal appeal within 180 days citing specific plan language. Escalate in parallel to HR/benefits — the employer can grant exceptions the PBM cannot. Include FDA indication documentation, BMI/A1c records, comorbidities, and prior-therapy failures. After internal appeals, ERISA permits federal court review.

GLP1Zoom is not an insurance company, broker, or health plan. We summarize general payer patterns from public plan documents and statute to help you ask the right questions. Always verify current coverage with your plan's member services. Full disclaimer.